245 related articles for article (PubMed ID: 1646331)
1. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.
Gozes I; McCune SK; Jacobson L; Warren D; Moody TW; Fridkin M; Brenneman DE
J Pharmacol Exp Ther; 1991 Jun; 257(3):959-66. PubMed ID: 1646331
[TBL] [Abstract][Full Text] [Related]
2. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
3. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors.
Gozes I; Lilling G; Glazer R; Ticher A; Ashkenazi IE; Davidson A; Rubinraut S; Fridkin M; Brenneman DE
J Pharmacol Exp Ther; 1995 Apr; 273(1):161-7. PubMed ID: 7714762
[TBL] [Abstract][Full Text] [Related]
4. A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes.
Gozes Y; Brenneman DE; Fridkin M; Asofsky R; Gozes I
Brain Res; 1991 Feb; 540(1-2):319-21. PubMed ID: 1647246
[TBL] [Abstract][Full Text] [Related]
5. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
[TBL] [Abstract][Full Text] [Related]
6. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos.
Gressens P; Hill JM; Gozes I; Fridkin M; Brenneman DE
Nature; 1993 Mar; 362(6416):155-8. PubMed ID: 8383805
[TBL] [Abstract][Full Text] [Related]
7. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor.
Sreedharan SP; Patel DR; Huang JX; Goetzl EJ
Biochem Biophys Res Commun; 1993 Jun; 193(2):546-53. PubMed ID: 8390245
[TBL] [Abstract][Full Text] [Related]
8. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
[TBL] [Abstract][Full Text] [Related]
9. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
Laburthe M; Couvineau A; Rouyer-Fessard C
Mol Pharmacol; 1986 Jan; 29(1):23-7. PubMed ID: 3003561
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
[TBL] [Abstract][Full Text] [Related]
12. Distribution of vasoactive intestinal polypeptide (VIP) binding in circular muscle and characterization of VIP binding in canine small intestinal mucosa.
Mao YK; Barnett W; Coy DH; Tougas G; Daniel EE
J Pharmacol Exp Ther; 1991 Sep; 258(3):986-91. PubMed ID: 1653848
[TBL] [Abstract][Full Text] [Related]
13. Cyclic AMP-dependent protein kinase in Molt 4b lymphoblasts: identification by photoaffinity labeling and activation in intact cells by vasoactive intestinal polypeptide (VIP) and peptide histidine isoleucine (PHI).
O'Dorisio MS; Wood CL; Wenger GD; Vassalo LM
J Immunol; 1985 Jun; 134(6):4078-86. PubMed ID: 2985703
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide receptor regulation of cAMP accumulation and glycogen hydrolysis in the human Ewing's sarcoma cell line WE-68.
Van Valen F; Jürgens H; Winkelmann W; Keck E
Cell Signal; 1989; 1(5):435-46. PubMed ID: 2561912
[TBL] [Abstract][Full Text] [Related]
15. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
Moody TW; Zia F; Draoui M; Brenneman DE; Fridkin M; Davidson A; Gozes I
Proc Natl Acad Sci U S A; 1993 May; 90(10):4345-9. PubMed ID: 8389448
[TBL] [Abstract][Full Text] [Related]
16. VIP receptor subtypes in mouse cerebral cortex: evidence for a differential localization in astrocytes, microvessels and synaptosomal membranes.
Martin JL; Feinstein DL; Yu N; Sorg O; Rossier C; Magistretti PJ
Brain Res; 1992 Jul; 587(1):1-12. PubMed ID: 1326373
[TBL] [Abstract][Full Text] [Related]
17. Interaction between catecholamines and vasoactive intestinal peptide in cultured astrocytes.
Hansson E; Rönnbäck L
Neuropharmacology; 1988 Mar; 27(3):295-300. PubMed ID: 2836754
[TBL] [Abstract][Full Text] [Related]
18. A VIP hybrid antagonist: from developmental neurobiology to clinical applications.
Gozes I; Fridkin M; Brenneman DE
Cell Mol Neurobiol; 1995 Dec; 15(6):675-87. PubMed ID: 8719036
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist.
Gozes I; Meltzer E; Rubinrout S; Brenneman DE; Fridkin M
Endocrinology; 1989 Dec; 125(6):2945-9. PubMed ID: 2583049
[TBL] [Abstract][Full Text] [Related]
20. Characterization of receptors for vasoactive intestinal peptide solubilized from the lung.
Paul S; Said SI
J Biol Chem; 1987 Jan; 262(1):158-62. PubMed ID: 3025200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
